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Abstract
Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with
cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other
diseases. Concentrations of 25-hydroxyvitamin D (25(OH)D) (25D) are considered as the best indicator of
total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is
well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain
and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D
deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may
establish a role for Vitamin D supplementation in individuals at increased CV risk.
The increase in obesity rates presents a major public health concern. In Europe,
its prevalence is in the range of 10–25% in men and 10–30% in women1,2.
Obesity is associated with a number of co-morbidities such as cardiovascular
(CV) disease, hypertension, stroke, type 2 diabetes mellitus (T2DM), dyslipide-
mia, osteoarthritis and some cancers3,4.
The role of vitamin D in calcium and bone metabolism is well established.
Today, vitamin D deficiency is a pandemic and has been implicated in several
diseases including CV morbidity and mortality5–8, metabolic syndrome9–11 and
T2DM12–14.
Which proteins link vitamin D to obesity has been investigated in genetic
studies15. There is also evidence that non-genomic mechanisms including
protein expression, oxidative stress, inflammation and cellular metabolism
are involved15. However, it is unlikely that vitamin D can cause weight loss
although supplements may be associated with a small improvement in cardio-
vascular risk16–19. After absorption vitamin D is sequestered and stored in
tissues (e.g. adipose and muscle)20. Radio-labeled vitamin D3 has been injected
into individuals and the highest levels of activity and radioactivity has been
shown in adipose tissue21.
Serum concentrations of 25-hydroxyvitamin D (25(OH)D) (25D) are con-
sidered as the best indicator of total body vitamin D stores, and their value
reflects the total dietary intake and exposure to ultraviolet radiation22.
The association between reduced 25D concentrations and obesity is well
known, but the mechanisms are not fully understood. The question still remains
as to what the health consequences of these reduced 25D levels are, especially in
obesity with dysfunctional adipose tissue and insulin resistance.
An inverse association between 25D levels and insulin resistance has been
reported and lower vitamin D status was accompanied by higher glucose con-
centrations23–25. In patients with T2DM, it has been reported that glucose
intolerance improves after vitamin D supplementation25,26. There is also an
inverse association between 25D concentration and body mass index
(BMI)27–30. The mechanisms involved in lower 25D concentrations in obese
individuals are not fully described, but it is possible that sequestration of
vitamin D metabolites in fat compartments decreases their bioavailability29.
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Several clinical and epidemiological studies reported that
obese subjects have lower serum concentrations of 25D
with a negative correlation of vitamin D concentrations
with BMI and waist circumference31,32. Additionally,
fat mass is inversely associated with 25D levels33–38.
Another explanation is that obese people have
vitamin D deficiency because of less sun exposure due
to a sedentary lifestyle37. A study involving 243
adults reported a decrease of 0.74 nmol/l of serum 25D
per 1 kg/m2 increase in BMI38.
The role of vitamin D supplementation is still uncer-
tain. In Norway, 334 overweight/obese participants were
treated with calcium plus vitamin D or placebo during
1 year; no change in weight was observed17.
Botella-Carretero et al. reported a negative correlation
between serum 25D concentrations and serum triglycer-
ides, as well as a positive association between serum 25D
concentrations and serum high density lipoprotein choles-
terol (HDL-C) concentrations39,40. Another study failed
to find any effect of raising 25D levels on plasma lipids41
while a similar study found that calcium and vitamin D
supplementation resulted in decreased serum low density
lipoprotein cholesterol levels42. As dyslipidemia is an
important CV risk factor, there is a need for randomized
controlled trials to clarify the possible effects of vitamin D
on atherogenic dyslipidemia, especially in obese persons.
Several studies have proposed a relationship between
vitamin D status and insulin resistance23,24,43. Pancreatic
b-cells express vitamin D receptors, so a possible explana-
tion is that vitamin D acts on these receptors44 and in that
way can indirectly influence calcium entering the
b-cells45; thus vitamin D may affect insulin secretion.
There is evidence suggesting that vitamin D deficiency
is a potential risk factor for CV disease46–49. Giovannucci
et al. in a 10 year follow up clinical study found that men
with vitamin D deficiency were at higher risk for myocar-
dial infarction50. Wang et al. reported that vitamin D defi-
ciency among participants with hypertension is related
with a two-fold increased CV risk51.
Recently, Alhamad et al.52 reported the findings of a
study related to the vitamin D deficiency among the
elderly. They found that in elderly people, lower serum
vitamin D levels were inversely correlated with values
of HbA1c (an index of glycemic control) and HDL-C.
In addition, they show that after supplementation,
improvement in vitamin D deficiency was small but
significant.
In conclusion, vitamin D deficiency seems to promote
the development of a more proatherogenic cardiometa-
bolic risk profile in the obese as well in persons with
increased fat mass. Future researchmay show that measure-
ment of vitamin D levels can help to identify individuals at
greater CV risk. This could be the basis for the design of
future intervention trials in the obese.
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